- Galena Biopharma (GALE) adds to Monday's gains, rising 3.6% in premarket action.
- The company says it has struck a strategic development and commercialization deal with Dr. Reddy's Laboratories (RDY) for NeuVax in India.
- Details are sparse at this juncture.
- GALE CEO Mark Ahn says the partnership "is consistent with [GALE's] strategy to expand the clinical utility of NeuVax in unmet medical needs while simultaneously increasing the commercial footprint of this innovative cancer immunotherapy." (PR)